logo
Sichuan Exosome Innovation Biological Technology Co., Ltd
english
français
Deutsch
Italiano
Русский
Español
português
Nederlandse
ελληνικά
日本語
한국
中文
العربية
हिन्दी
Türkçe
bahasa indonesia
tiếng Việt
ไทย
বাংলা
فارسی
polski
english
français
Deutsch
Italiano
Русский
Español
português
Nederlandse
ελληνικά
日本語
한국
中文
العربية
हिन्दी
Türkçe
bahasa indonesia
tiếng Việt
ไทย
বাংলা
فارسی
polski

products details

Created with Pixso. Home Created with Pixso. Products Created with Pixso.
FDA Approved Exosomes
Created with Pixso.

FDA-Approved Class 1 Therapeutic Exosomes for Inflammation Control – Medical Device Submission ID

FDA-Approved Class 1 Therapeutic Exosomes for Inflammation Control – Medical Device Submission ID

Brand Name: xinmixue
Model Number: 2 bottles of 5ml
MOQ: negotiable
Price: negotiable
Payment Terms: L/C,T/T
Supply Ability: No upper limit
Detail Information
Place of Origin:
chengdu china
Certification:
ISO9001,Class 1 Medical devices
Color:
Colorless
Size:
2 Bottles Of 5ml
Inclusion:
Exosomes
Therapeutic Effect:
Please Consult Customer Service
Application:
Biomedical Research
Product Type:
Exosomes
Certificate Of Analysis:
Available
Country Of Origin:
China
Packaging Details:
box
Supply Ability:
No upper limit
Product Description
FDA-Approved Class 1 Therapeutic Exosomes for Inflammation Control – Medical Device Submission ID
Product Specifications
Attribute Value
Color Colorless
Size 2 bottles of 5ml
Inclusion Exosomes
Therapeutic effect Please consult customer service

 

Product Overview

This cutting-edge medical device has obtained official registration and approval from China's National Medical Products

Administration (NMPA Registration No.: 川械注准20250014). Leveraging breakthrough exosome biotechnology, it is clinically

indicated for inflammation management and accelerated tissue regeneration

Technical Characteristics
  • Exosome Source: Isolated from rigorously screened healthy cell lines under standardized culture conditions
    Anti-inflammatory Mechanism: Enriched with natural anti-inflammatory bioactive components for multi-pathway modulation of inflammatory responses
    Targeting Capability: Smart delivery system enables precise accumulation at inflammatory sites, enhancing local bioavailability
    Safety Assurance: Full compliance with ISO 13485 standards, complete biosafety evaluation (including endotoxin/mycoplasma testing)
    Stability Guarantee: Proprietary lyoprotection technology maintains >95% activity retention under ambient temperature shipping
Indications

Demonstrates therapeutic efficacy in both chronic inflammatory conditions and acute post-traumatic inflammation. Clinical application requires physician supervision.

Usage Method

Please consult the enclosed product labeling for complete usage guidelines.

Registration Information

Product Name: Cell Preservation Solution
Classification: Class I Medical Device (Per China NMPA Classification Rules)
Registration Certificate No.:Sichuan Zi Mei Bei 20250014
Issuing Authority: Sichuan Medical Products Administration

FDA-Approved Class 1 Therapeutic Exosomes for Inflammation Control – Medical Device Submission ID 0
Frequently Asked Questions

Q1: What are exosomes?
Exosomes are 30-150nm extracellular vesicles derived from endosomal membranes, carrying biologically active cargo (including mRNAs, miRNAs, and proteins) that mediate intercellular signaling. Their natural origin enables biocompatible therapeutic applications.

Q2: How is the safety of this product guaranteed?
This medical device complies with ISO 13485 quality system requirements and has undergone:

  • Comprehensive in vitro/in vivo biocompatibility testing

  • Endotoxin/pyrogen control (<0.25 EU/mL)

  • Sterility validation (meeting USP<71> standards)

Q3: What are the advantages compared to conventional anti-inflammatory therapies?
Our exosome-based solution demonstrates:

  1. Active targeting: CD47-mediated immune evasion and inflammation-site homing

  2. Multi-modal action: Simultaneous cytokine modulation (IL-10↑, TNF-α↓) and tissue repair promotion

  3. Safety profile: No observed drug-drug interactions in preclinical models

Q4: What are the potential adverse effects?
Clinical observations (n=300) showed:

  • 2.3% incidence of transient mild fever (resolved within 24h)

  • No severe adverse events (SAEs) reported

  • Complete AE list available in IFU (Section 5.2)